To include your compound in the COVID-19 Resource Center, submit it here.

AstraZeneca Phase III Exanta data

AstraZeneca (AZN; LSE:AZN) said its Exanta ximelagatran met the primary endpoint of

Read the full 122 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE